<SEC-DOCUMENT>0001213900-20-018777.txt : 20200728
<SEC-HEADER>0001213900-20-018777.hdr.sgml : 20200728
<ACCEPTANCE-DATETIME>20200728081748
ACCESSION NUMBER:		0001213900-20-018777
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200723
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200728
DATE AS OF CHANGE:		20200728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROONE MEDICAL TECHNOLOGIES Corp
		CENTRAL INDEX KEY:			0001500198
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				270863354
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54716
		FILM NUMBER:		201051820

	BUSINESS ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344
		BUSINESS PHONE:		(952) 426-1383

	MAIL ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Original Source Entertainment, Inc.
		DATE OF NAME CHANGE:	20100830
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea124591-8k_neuroone.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WASHINGTON, D.C.&nbsp; 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of Earliest Event Reported):
<B>July 23, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 34%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 31%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>000-54716</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>27-0863354</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">of incorporation)</P></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>7599 Anagram Dr., Eden Prairie, MN 55344</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices and
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>952-426-1383</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant's telephone number including area
code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant's former name or former address,
if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9744; Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9744; Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9744; Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9744; Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Emerging Growth Company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&#9744;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 1.01 Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Conversion of 2020 Notes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As previously disclosed in a Current Report
on&nbsp;Form 8-K&nbsp;filed by NeuroOne Medical Technologies Corporation (the &ldquo;<B><I>Company</I></B>&rdquo;) with the Securities
and Exchange Commission (the &ldquo;<B><I>SEC</I></B>&rdquo;) on May 1, 2020 (the &ldquo;<B><I>Initial Form 8-K</I></B>&rdquo;),
on April 30, 2020, the Company entered into a Subscription Agreement (the &ldquo;<B><I>Subscription Agreement</I></B>&rdquo;) with
certain accredited investors (the &ldquo;<B><I>Subscribers</I></B>&rdquo;), pursuant to which the Company, in a private placement
(the &ldquo;<B><I>2020 Private Placement</I></B>&rdquo;), agreed to issue and sell to the Subscribers 13% convertible promissory
notes (each, a &ldquo;<B><I>2020 Note</I></B>&rdquo; and collectively, the &ldquo;<B><I>2020 Notes</I></B>&rdquo;) and warrants
to purchase shares of the Company&rsquo;s common stock, par value $0.001 per share (&ldquo;<B><I>Common Stock</I></B>&rdquo;).
Capitalized terms not otherwise defined herein shall have the meanings assigned to such terms in the Initial Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Between July 1, 2020 and July 22, 2020, certain
Subscribers elected to convert $1,720,000.55 of the outstanding principal and interest of such Subscribers&rsquo; 2020 Notes into
1,977,991 shares of Common Stock, and on July 23, 2020, the remaining $1,613,961.11 of the outstanding principal and interest of
the 2020 Paulson Notes were automatically converted into 1,605,532 shares of Common Stock following the announcement of a Strategic
Transaction (as defined in the 2020 Paulson Notes) (together, the &quot;<B><I>Conversion Shares</I></B>&quot;). Between May 1,
2020 and July 23, 2020, an aggregate of $5,204,800.67 of the outstanding principal and interest of the 2020 Notes converted into
5,617,866 shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">1</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 3.02. Unregistered Sales of Equity Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Private Placement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The description set forth in Item 1.01 above is hereby incorporated
by reference into this Item 3.02.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As described more fully in Item 1.01, the Company issued Conversion
Shares to certain Subscribers, who are accredited investors, in reliance on the exemption from registration provided by Section
4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;) and Rule 506 of Regulation D
promulgated thereunder. The Company is relying on this exemption from registration based in part on representations made by the
Subscribers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Conversion Shares have not been registered under the Securities
Act or applicable state securities laws and may not be offered or sold in the United States absent registration under the Securities
Act or an exemption from such registration requirements. Neither this Current Report on Form 8-K nor any exhibit attached hereto
shall constitute an offer to sell or the solicitation of an offer to buy the Conversion Shares or any other securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Attached as Exhibit 99.1 is a copy of the
press release issued by NeuroOne on July 28, 2020 announcing the conversion of the remaining 2020 Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>(d) Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 6%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 93%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #0000EE"><U><A HREF="ea124591ex99-1_neuroone.htm" STYLE="-sec-extract: exhibit">Press Release dated July 28, 2020 issued by NeuroOne.</A></U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>NEUROONE MEDICAL TECHNOLOGIES CORPORATION </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 63%"><FONT STYLE="font-size: 10pt">Dated: July 28, 2020</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ David Rosa</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">David Rosa</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">3</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea124591ex99-1_neuroone.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; background-color: white"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; background-color: white"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 52px; width: 275px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-align: center; background-color: white"><B>NeuroOne
Medical Technologies Corporation Reduces Debt by $3.3 Million and Strengthens Balance Sheet</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-align: center; background-color: white"><I>Company
Preparing for Commercialization of Thin Film Electrodes Technology </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Eden Prairie, MN &ndash; July 28, 2020 &ndash; </B>NeuroOne
Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes
for patients suffering from neurological disorders, today announces that during July, 2020, the Company retired approximately $3.3
million of debt, strengthening the Company&rsquo;s balance sheet. NeuroOne is now transitioning to advancing commercialization
planning, building its financial infrastructure, and additional product development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&ldquo;Now that we have shored up our balance sheet, we are
well positioned to prepare for commercialization of our EVO Cortical Electrode product line with Zimmer Biomet, our strategic commercialization
partner, accelerate additional research and development efforts, and explore uplisting to a national securities exchange,&rdquo;
says Dave Rosa, president and CEO, NeuroOne.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">The result of a collaboration with the University of Madison-Wisconsin&rsquo;s
Alumni Research Foundation and the Mayo Foundation for Medical Education and Research, EVO is designed for the diagnosis and treatment
of various neurological conditions, including epilepsy. EVO is based on thin-film, high-definition electrodes designed to record
and monitor brain activity and stimulate brain tissue for up to 30 days. Additional potential future applications include: Parkinson&rsquo;s
disease (PD), brain tissue ablation and chronic pain due to failed back surgeries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">EVO received FDA 510(k) clearance in December 2019. By the
end of 2020, NeuroOne plans to complete a 510(k) submission to the FDA of its stereoelectroencephalography (sEEG) Depth Electrode.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0"><B>About NeuroOne</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0">NeuroOne Medical Technologies Corporation is a developmental
stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation
solutions for patients suffering from epilepsy, Parkinson's disease, essential tremors and other related neurological disorders
that may improve patient outcomes and reduce procedural costs. Visit <U>https://www.n1mtc.com/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 7.5pt; background-color: white"><B>Forward Looking Statements</B><BR>
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained
in this presentation may be a forward<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>looking statement that reflects
the Company's current views about future events and are subject to known and unknown risks, uncertainties and other factors that
may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed
or implied by these forward-looking statements. In some cases, you can identify forward<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>looking
statements by the words &quot;may,&quot; &quot;might,&quot; &quot;will,&quot; &quot;could,&quot; &quot;would,&quot; &quot;should,&quot;
&quot;expect,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;objective,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot;
&quot;predict,&quot; &quot;project,&quot; &quot;potential,&quot; &quot;target,&quot; &quot;seek,&quot; &quot;contemplate,&quot;
&quot;continue&quot; and &quot;ongoing,&quot; or the negative of these terms, or other comparable terminology intended to identify
statements about the future. Forward<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>looking statements may include
statements regarding the timing of the Company's regulatory submissions, uplisting to a national securities exchange, potential
regulatory approval, commercialization of the technology, business strategy, market size, potential growth opportunities, plans
for product applications and product development, future operations, future efficiencies, and other financial and operating information.
Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements
are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot
be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control,
including our ability to raise additional funds, uncertainties inherent in the development process of our technology, delays in
the manufacturing process, changes in regulatory requirements or decisions of regulatory authorities, our ability to uplist to
a national securities exchange, the size and growth potential of the markets for our technology, our ability to serve those markets,
the rate and degree of market acceptance of our products, clinical trial patient enrollment, the results of clinical trials, future
competition, the actions of third-party clinical research organizations, suppliers and manufacturers, our ability to protect our
intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading &quot;Risk
Factors&quot; in our filings with the Securities and Exchange Commission. These forward<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>looking
statements speak only as of the date of this press release and the Company undertakes no obligation to revise or update any forward<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>looking
statements for any reason, even if new information becomes available in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 7.5pt; background-color: white"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; background-color: white"><B>Media:</B><BR>
Brittany Tedesco<BR>
CPR Communications<BR>
btedesco@cpronline.com<BR>
201.641.1911 x 14</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 7.5pt; background-color: white"><B>Investor Relations Contact</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 7.5pt; background-color: white">Leah Noaeill<BR>
Sr. Director of Marketing<BR>
NeuroOne Medical Technologies Corporation<BR>
leahn@n1mtc.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 7.5pt; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 7.5pt; background-color: white">&quot;Caution: Federal law restricts
this device to sale by or on the order of a physician.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 7.5pt; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 7.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T 1,# 2(  A$! Q$!_\0
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MF-6G.FE&2>IC@*<X3;DK:'DGQ>_Y'&+_ *\T_P#0GJ]\&?\ D,:E_P!>Z_\
MH5:7Q$\%:YXA\1QWFG6R20"W6,L957D%CT)]Q5KX;>$=8\.:E>S:E;I$DL(5
M2LBMDYSV-$JM/ZER<RO;;YB5*?UOFMI<\W\<:=)IGC'4HG4@23-,A]5<[A_/
M'X5T_P .8/">I64UGK-O;?;UD+1M,Y7>A X'(&00>/>O0O&/@NT\66J%G\B]
MB!$4X&>/[K#N/Y5Y#J'PX\3V$I4:>;A!TDMV# _AU_2M*=>G7HJ#ERR^XBI1
MG1JN:CS([[78/AUX?$8N;"":1SQ%;N78#U/S<"JNA:AX U'6[2VT[0YQ=M(#
M$Q0X4CG)^<],9KAK3X?>*+R4(-*EB'=IB$ _.O6/!'@.#PLK75Q(MQJ,B[2Z
MCY8QZ+_C65;V5*F[U'*7J:TO:5)_ DO0[*BBBO(/3"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
